We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

39 hedge funds and large institutions have $149M invested in OnKure Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 5

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

9% more capital invested

Capital invested by funds: $137M → $149M (+$12.2M)

3% more funds holding

Funds holding: 38 → 39 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.39% less ownership

Funds ownership: 7.52% → 7.13% (-0.39%)

Holders
39
Holders Change
+1
Holders Change %
+2.63%
% of All Funds
0.6%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
5
Increased
14
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$184K
2
BlackRock
BlackRock
New York
+$166K
3
Bank of America
Bank of America
North Carolina
+$111K
4
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$99K
5
PCM
Pinz Capital Management
New York
+$67.6K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$6.33M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.11M
3
RCM
RA Capital Management
Massachusetts
-$464K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$74.5K
5
Geode Capital Management
Geode Capital Management
Massachusetts
-$10.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$40.9M – – –
NHAS
2
Novo Holdings A/S
Denmark
$29.3M – – –
RVM
3
RiverVest Venture Management
Missouri
$20.6M – – –
A
4
Abingworth
United Kingdom
$17.7M – – –
RSCM
5
Rock Springs Capital Management
Maryland
$9.77M – – –
ACM
6
Aisling Capital Management
New York
$7.58M – – –
TCM
7
Tybourne Capital Management
Hong Kong
$6.41M – – –
Franklin Resources
8
Franklin Resources
California
$3.85M – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$3.14M -$74.5K -1,015 -3%
BlackRock
10
BlackRock
New York
$2.71M +$166K +2,260 +8%
IC
11
Ikarian Capital
Texas
$1.5M – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.02M -$10.5K -143 -1%
BCM
13
Bridgeway Capital Management
Texas
$855K – – –
State Street
14
State Street
Massachusetts
$753K +$15.1K +205 +2%
Northern Trust
15
Northern Trust
Illinois
$544K +$33.2K +452 +8%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$314K -$1.11M -15,080 -80%
Bank of America
17
Bank of America
North Carolina
$282K +$111K +1,509 +84%
PCM
18
Pinz Capital Management
New York
$242K +$67.6K +921 +48%
Millennium Management
19
Millennium Management
New York
$214K +$184K +2,499 New
Charles Schwab
20
Charles Schwab
California
$161K +$40.1K +546 +41%
BFM
21
Boothbay Fund Management
New York
$151K – – –
Federated Hermes
22
Federated Hermes
Pennsylvania
$145K – – –
Bank of New York Mellon
23
Bank of New York Mellon
New York
$116K +$5.43K +74 +6%
Qube Research & Technologies (QRT)
24
Qube Research & Technologies (QRT)
United Kingdom
$115K +$99K +1,348 New
Wells Fargo
25
Wells Fargo
California
$68K +$58.6K +798 New
1
2

OKUR Hedge Fund Activity: Q4 2021 in Review

39 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q4 2021, worth a combined $149M — up 8.9% from $137M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new OKUR positions and 3 closed out — a net gain of 2 holders — while 14 added to existing stakes and 5 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $184K. The largest seller was Deerfield Management, exiting entirely with an estimated $6.33M sold.

  • 39 institutional investors held OnKure Therapeutics (OKUR) as of Q4 2021, up from 38 in Q3 2021.
  • Funds reported $149M of OnKure Therapeutics stock for Q4 2021, up 8.9% quarter-over-quarter.
  • 5 funds opened new OnKure Therapeutics positions in Q4 2021 and 3 closed out, a net change of +2 holders.
  • The largest OnKure Therapeutics buyer in Q4 2021 was Millennium Management, an estimated $184K added.
  • The largest OnKure Therapeutics seller in Q4 2021 was Deerfield Management, an estimated $6.33M sold.

Based on aggregated 13F filings for Q4 2021.